Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORWARD: Furmonertinib in Adjuvant Treatment of EGFR-Mutated NSCLC
NCT04853342Phase 3Recruiting
- Sponsor
- Allist Pharmaceuticals
- Start
- Jun 2021
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung carcinoma (NSCLC) comparing Furmonertinib with Placebo (2 arms). Primary endpoint: Disease-Free Survival at 5 years. Started Jun 2021; status: recruiting.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung carcinoma (NSCLC)
Beyond the preview
Go deeper on NCT04853342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04853342.